PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics

PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics

PTC Therapeutics, Inc. , today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc., a private biotechnology company focused on the advancement of innovative gene therapy programs for rare genetic disorders that affect the central nervous system . "We are excited to complete the acquisition and welcome the Agilis employees to PTC," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We have added a team with exceptional gene therapy experience, a targeted micro-delivery gene therapy platform that has demonstrated durable clinical benefit, as well as gene therapy manufacturing and R&D capabilities.

from Biotech News